AAPS Summer Scientific Forum
The AAPS Summer Scientific Forum makes AAPS the premier scientific convener of the pharmaceutical industry: breadth, depth, and quality science. Attend this meeting for depth in the latest bioanalysis or pharmaceutical analysis science and seize the opportunity to cross-connect with other scientists in shared high-level sessions focused on key regulatory issues facing these scientific areas.
Date: Monday, July 22 – Thursday, July 25, 2024
Location: Intercontinental Kansas City at the Plaza, Kansas City, MO
Booth: #5
JOIN US!
Join us Tuesday, July 23rd at the AAPS Summer Scientific Forum in Kansas City, Missouri – attend our talk, “Practical Approaches to Characterizing Charged Variants” or connect with our analytical experts at booth #5. Complete the form to schedule a meeting with Catalent at the AAPS Summer Scientific Forum!
FEATURED SPEAKING SESSION
Title: Practical Approaches to Characterizing Charged Variants
Date: Tuesday, July 23, 2024
Time: 11:30 am – 12:00 pm CDT
Location: Salon III
Description: Biotherapeutics heterogeneity has implications for the efficacy and stability of the final Biotherapeutic or Biosimilar Products. Charged Variant profiles are of particular utility since many important Post-translational Modifications (PTMs) impart or alter the charge (pI) on the molecule. The determination of some level of structure-function assessment supports product lifecycle critical quality attributes which are considered with respect to product release and stability specifications.
SPEAKER
Shawn Fitzgibbons, MS Chemistry
Biologics Senior Manager
Catalent Pharma Solutions
Kansas City, Missouri
ABOUT CATALENT BIOLOGICS
For nearly three decades, Catalent Biologics has built capabilities and expertise in development, manufacturing, and analytical services, now spanning new biological entities, biosimilars, plasmid DNA, cell and gene therapies, vaccines, sterile injectables, mRNA, and antibody-drug conjugates. It has developed processes for hundreds of biologic products, with more than 50 commercially approved products that have employed Catalent Biologics’ manufacturing and packaging capabilities as well as 20 approved/authorized biotherapeutics that have leveraged GPEx® cell line development technology.
Using advanced technologies and tailored solutions from clinical to commercial supply, Catalent brings better biologic and advanced treatments to patients, faster.
